title: Phenotypic characterization of nonsocial behavioral impairment in neurexin 1α knockout rats.
abstract: Neurexins are neuronal presynaptic proteins that play a key role in mediation of synapse formation. Heterozygous partial deletions in the neurexin-1 gene (NRXN1, 2p16.3) have been observed in autism spectrum disorder (ASD) patients. NRXN1-α knockout (KO) mice present behavioral impairments that resemble some of the core ASD symptoms of social impairment and inflexibility/stereotypy. At present, a thorough assessment of cognitive function has yet to be completed. Rats, containing a biallelic deletion of the NRNX1-α gene on a Sprague Dawley background were compared to littermate wild types across a range of tasks designed to test functional domains disrupted in ASD and other neurodevelopmental disorders, including sensory perception (prepulse inhibition), attention (latent inhibition), associative learning (instrumental and Pavlovian conditioning), and memory (rewarded alternation T maze and spatial discrimination). NRXN1α KO rats were found to present with large and persistent nonsocial deficits, including hyperactivity, deficits in simple instrumental learning, latent inhibition, and spatial-dependent learning. No deficit in sensorimotor gating was observed, despite the presence of an exaggerated startle response. Although KO animals were also able to learn a simple Pavlovian conditioning discrimination, they did display impaired latent inhibition. The presence of pronounced impairments in several domains in NRXN1α KO rats clearly suggests that nonsocial cognitive deficits can also be measured in an animal model of ASD. Further exploration of those deficits, both clinically and preclinically, as planned in the Innovative Medicines Initiative's European Autism Interventions: A Multicenter Study for Developing New Medications program, may help to better understand the brain circuitry involved in ASD and therefore open new avenues to advance novel therapies.
authors.affiliation: In Vivo Pharmacology, Lilly Research Centre, Lilly Research Laboratories, Eli Lilly & Co. Ltd.
authors.forename: Frederic
authors.initials: F
authors.lastname: Esclassan
authors.affiliation: In Vivo Pharmacology, Lilly Research Centre, Lilly Research Laboratories, Eli Lilly & Co. Ltd.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Francois
authors.affiliation: Neurosymptomatics, Lilly Research Centre, Lilly Research Laboratories, Eli Lilly & Co. Ltd.
authors.forename: Keith G
authors.initials: KG
authors.lastname: Phillips
authors.affiliation: In Vivo Pharmacology, Lilly Research Centre, Lilly Research Laboratories, Eli Lilly & Co. Ltd.
authors.forename: Sally
authors.initials: S
authors.lastname: Loomis
authors.affiliation: In Vivo Pharmacology, Lilly Research Centre, Lilly Research Laboratories, Eli Lilly & Co. Ltd.
authors.forename: Gary
authors.initials: G
authors.lastname: Gilmour
mesh_terms: D000818:Animals; D001245:Association Learning / Q000502:physiology; D001288:Attention / Q000502:physiology; D001522:Behavior, Animal / Q000502:physiology*; D002659:Child Development Disorders, Pervasive / Q000235:genetics* / Q000523:psychology*; D004195:Disease Models, Animal; D005260:Female; D017353:Gene Deletion; D055786:Gene Knockout Techniques; D006023:Glycoproteins / Q000235:genetics*; D008297:Male; D009479:Neuropeptides / Q000235:genetics*; D010641:Phenotype; D065808:Prepulse Inhibition / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D055647:Rats, Transgenic; D055139:Sensory Gating / Q000235:genetics; D065852:Spatial Memory / Q000502:physiology
chemical_list: D006023:Glycoproteins; D009479:Neuropeptides; C112162:neurexophilin